Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
France
In shortBiomerieux SA is profitable, generates cash and holds more cash than debt, with revenue growing (+2.3% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 12.8% | 59/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 9.8% | 59/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 9.6% | 48/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 9.0% | 60/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | – | n/a |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.11× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 19.4% | 97/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.98× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 3.0% | 100/100 |
| Operating margin volatility | 4.5% | 68/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 4.3% | 40/100 |
|---|---|---|
| EPS growth, 3-year average | -4.4% | 3/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 3,376 | 3,589 | 3,675 | 3,980 | 4,070 |
| Cost of revenue | 1,413 | 1,580 | 1,617 | 1,765 | 1,761 |
| Gross profit | 1,964 | 2,009 | 2,057 | 2,215 | 2,309 |
| Research & development | 389 | 447 | 460 | 492 | 507 |
| Operating income | 784 | 587 | 439 | 589 | 521 |
| Income tax | 176 | 140 | 115 | 154 | 129 |
| Net income | 601 | 452 | 358 | 432 | 398 |
| Diluted EPS | €5.06 | €3.82 | €3.01 | €3.64 | €3.34 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
Not computed: a required balance-sheet item is missing.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Dec 31, 2025 · Data updated Mar 16, 2026